AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35957800 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody negative participants
Number of subjects: 1082
Study 35957800 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported COVID-19 symptoms
Number of subjects: 1082
Study 35957800 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1082
Study 35957800 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasians
Number of subjects: 1082
Study 35957800 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-clinicians
Number of subjects: 1082
Study 35957800 — intervention group
Group type: EXPERIMENTAL
Intervention: Age < 44 years
Number of subjects: 1082
Study 35957800 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff aged < 44 years
Number of subjects: 1082
Study 35957800 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported COVID symptoms
Number of subjects: 1082
Study 35957800 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctors
Number of subjects: 1082
Study 35957957 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology (PP) and motivational interviewing (MI) intervention
Number of subjects: 47
Study 35957960 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigil (1 × 10e6-10e7 cells/dose intradermally, up to 12 doses) and durvalumab (1500 mg/dose intravenous infusion, up to 12 months)
Number of subjects: 13
Study 35957960 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigil plus durvalumab
Number of subjects: 13
Study 35958254 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented oyster (FO) 1,200 mg daily for 12 weeks
Number of subjects: 54
Study 35958254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 35958254 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented oyster (FO)
Number of subjects: 54
Study 35958322 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib combined with epidermal growth factor receptor (EGFR) inhibitors in cohort A
Number of subjects: 82
Study 35958322 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib combined with EGFR inhibitors in cohort B
Number of subjects: 82
Study 35958322 — intervention group
Group type: COMPARATOR
Intervention: Control group (Cohort C)
Number of subjects: 82
Study 35958344 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent platinum-based chemoradiotherapy (CRT) followed by durvalumab maintenance treatment
Number of subjects: 40
Study 35958398 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic administration of aspirin (150 mg/day) in high-risk patients
Number of subjects: 0
Study 35958398 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester screening model using angiogenic markers (PlGF)
Number of subjects: 0
Study 35958398 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate Gaussian distribution model for PE risk calculation
Number of subjects: 0
Study 35958398 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt-1 values determination in high and intermediate risk patients
Number of subjects: 0
Study 35958875 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 108
Study 35958875 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 108
Study 35958875 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment
Number of subjects: 108
Study 35959207 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab plus standard of care
Number of subjects: 40
Study 35959207 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard of care
Number of subjects: 40
Study 35959564 — intervention group
Group type: COMPARATOR
Intervention: SBP < 160 mmHg in non-lacunar infarction group
Number of subjects: 1089
Study 35959564 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP ≥ 160 mmHg in non-lacunar infarction group
Number of subjects: 1089
Study 35959564 — intervention group
Group type: COMPARATOR
Intervention: Negative DWI
Number of subjects: 1089
Study 35959564 — intervention group
Group type: COMPARATOR
Intervention: Lacunar infarction
Number of subjects: 1089
Study 35960137 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-repetition maximum (1-RM) testing on a leg press
Number of subjects: 0
Study 35960137 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of testing after 1 failed attempt
Number of subjects: 0
Study 35960137 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-RM testing
Number of subjects: 0
Study 35960137 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple attempts at a failed load
Number of subjects: 0
Study 35960137 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-RM test
Number of subjects: 0
Study 35960332 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory five-drug cocktail (IDC) + Pembrolizumab + Radiotherapy (8Gyx3)
Number of subjects: 43
Study 35960719 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adjusted respiratory rate
Number of subjects: 1478
Study 35960719 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization/recurrent ED visits
Number of subjects: 1478
Study 35961055 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV episodes (nonhospitalized)
Number of subjects: 1040
Study 35961055 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza episodes (nonhospitalized)
Number of subjects: 1040
Study 35961062 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpal Tunnel Syndrome (CTS) patients
Number of subjects: 75
Study 35961062 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 75
Study 35961260 — intervention group
Group type: EXPERIMENTAL
Intervention: PO lipids (2.5 g/kg)
Number of subjects: 65
Study 35961260 — intervention group
Group type: COMPARATOR
Intervention: PO glucose (2.5 g/kg)
Number of subjects: 65
Study 35961260 — intervention group
Group type: COMPARATOR
Intervention: IV lipids (Intralipid/Liposyn II 20% at 0.35 ml/kg/h for 6 h)
Number of subjects: 65
Study 35961260 — intervention group
Group type: COMPARATOR
Intervention: IV glucose (10% glucose at 3.6 ml/kg/h for 6 h)
Number of subjects: 65
Study 35961260 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Meal Test (MMT)
Number of subjects: 65
Study 35961299 — intervention group
Group type: EXPERIMENTAL
Intervention: SalivaBio
Number of subjects: 30
Study 35961299 — intervention group
Group type: EXPERIMENTAL
Intervention: SaliPac
Number of subjects: 30
Study 35961299 — intervention group
Group type: COMPARATOR
Intervention: Salivette
Number of subjects: 30
Study 35961299 — intervention group
Group type: COMPARATOR
Intervention: Passive drool
Number of subjects: 30
Study 35961299 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage at RT and 4 °C
Number of subjects: 30
Study 35961299 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated freeze-thaw cycles
Number of subjects: 30
Study 35962206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralsetinib
Number of subjects: 29
Study 35962320 — intervention group
Group type: EXPERIMENTAL
Intervention: SALT (Staphylococcus aureus Surgical Site Infection Multinational Epidemiology in Europe) coding system
Number of subjects: 15432
Study 35962320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping country-specific procedure codes
Number of subjects: 15432
Study 35962339 — intervention group
Group type: EXPERIMENTAL
Intervention: three-month standard medical intervention to improve glycemic control
Number of subjects: 27
Study 35962339 — intervention group
Group type: COMPARATOR
Intervention: Control HDLs from healthy subjects carbamylated in vitro with potassium cyanate
Number of subjects: 27
Study 35962368 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate orally achieving a serum level of 0.2-0.4 mmol/l between month 6 and 12
Number of subjects: 12
Study 35962368 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 12
Study 35962446 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ5D
Number of subjects: 50
Study 35962446 — intervention group
Group type: EXPERIMENTAL
Intervention: AFEQT
Number of subjects: 50
Study 35962446 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT-Q (part 2)
Number of subjects: 50
Study 35962454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 122
Study 35962454 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids (GCs)
Number of subjects: 122
Study 35962459 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based model comprising imaging and clinical variables
Number of subjects: 1268
Study 35962459 — intervention group
Group type: COMPARATOR
Intervention: Clinical models without imaging metrics
Number of subjects: 1268
Study 35962841 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative measurements using the apex of the deep cartilage (ADC) as a landmark
Number of subjects: 52
Study 35962841 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative measurements using 3D-CT
Number of subjects: 52
Study 35962841 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 52
Study 35962841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bland-Altman plot analysis
Number of subjects: 52
Study 35962934 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-reducing agents (ARAs)
Number of subjects: 234
Study 35962934 — intervention group
Group type: COMPARATOR
Intervention: Non-acid-reducing agents (non-ARA group)
Number of subjects: 234
Study 35963263 — intervention group
Group type: EXPERIMENTAL
Intervention: GFAP
Number of subjects: 1696
Study 35963263 — intervention group
Group type: EXPERIMENTAL
Intervention: UCH-L1
Number of subjects: 1696
Study 35963263 — intervention group
Group type: EXPERIMENTAL
Intervention: GFAP and UCH-L1 (combined)
Number of subjects: 1696
Study 35963275 — intervention group
Group type: EXPERIMENTAL
Intervention: TB31F 1 mg/kg intravenous
Number of subjects: 25
Study 35963275 — intervention group
Group type: EXPERIMENTAL
Intervention: TB31F 3 mg/kg intravenous
Number of subjects: 25
Study 35963275 — intervention group
Group type: EXPERIMENTAL
Intervention: TB31F 10 mg/kg intravenous
Number of subjects: 25
Study 35963275 — intervention group
Group type: EXPERIMENTAL
Intervention: TB31F (all doses)
Number of subjects: 25
Study 35963275 — intervention group
Group type: EXPERIMENTAL
Intervention: TB31F serum concentration
Number of subjects: 25
Study 35963296 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Thickness (DT) in infants with BPD
Number of subjects: 111
Study 35963296 — intervention group
Group type: COMPARATOR
Intervention: Diaphragmatic Thickness (DT) in healthy control participants
Number of subjects: 111
Study 35963480 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-based adjuvant chemotherapy
Number of subjects: 1532
Study 35963480 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL densities
Number of subjects: 1532
Study 35963523 — intervention group
Group type: EXPERIMENTAL
Intervention: Guardant360 CDx
Number of subjects: 81
Study 35963523 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncomine Dx Target Test (ODxT)
Number of subjects: 81
Study 35963523 — intervention group
Group type: EXPERIMENTAL
Intervention: CHRYSALIS study
Number of subjects: 81
Study 35963650 — intervention group
Group type: EXPERIMENTAL
Intervention: Imperial RAPID risk score (five-item)
Number of subjects: 1189
Study 35963650 — intervention group
Group type: EXPERIMENTAL
Intervention: Imperial RAPID risk score (eight-item)
Number of subjects: 1189
Study 35963650 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID risk score
Number of subjects: 1189
Study 35963665 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of biliary acute pancreatitis according to evidence-based guidelines
Number of subjects: 5275
Study 35963665 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal timing for the index CT scan
Number of subjects: 5275
Study 35963741 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35963986 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 400 mg once daily
Number of subjects: 60
Study 35964087 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional imaging assessment of wound surface area (WSA)
Number of subjects: 30
Study 35964087 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician global assessment (CGA) of WSA
Number of subjects: 30
Study 35964087 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-related questionnaires and instruments (EBDASI, iscorEB)
Number of subjects: 30
Study 35964116 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health intervention (mobile app) for 3 months
Number of subjects: 65
Study 35964116 — intervention group
Group type: EXPERIMENTAL
Intervention: Usability assessment of the digital health solution
Number of subjects: 65
Study 35964124 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity (HI) group
Number of subjects: 577
Study 35964124 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Intensity (LMI) group
Number of subjects: 577
Study 35964141 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored physical activity intervention (ExerciseGuide UK)
Number of subjects: 35
Study 35964151 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to support attendance at initial mental health visits (details on specific strategies not provided)
Number of subjects: 65
Study 35964151 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral economics and implementation science frameworks applied to develop strategies
Number of subjects: 65
Study 35964324 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic smoking cessation counselling (intervention phase)
Number of subjects: 458
Study 35964324 — intervention group
Group type: COMPARATOR
Intervention: Opportunistic smoking cessation counselling (observation phase)
Number of subjects: 458
Study 35964548 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0
Study 35964548 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis for nausea and vomiting and proactive management of ILD/pneumonitis
Number of subjects: 0
Study 35964548 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies for T-DXd-related AEs (e.g. neutropenia, infusion-related reactions, alopecia, fatigue, left ventricular dysfunction)
Number of subjects: 0
Study 35964555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 27
Study 35964609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat (50 mg twice daily for 6 weeks, then 100 mg twice daily for 18 weeks)
Number of subjects: 20
Study 35964683 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided through-the-needle-biopsy (TTNB) sampling with next-generation sequencing (NGS) for molecular analysis
Number of subjects: 101
Study 35964847 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural CCTA
Number of subjects: 7034
Study 35964847 — intervention group
Group type: COMPARATOR
Intervention: No preprocedural CCTA
Number of subjects: 7034
Study 35965248 — intervention group
Group type: EXPERIMENTAL
Intervention: High stress hyperglycemia ratio (SHR) ≥1.24 in DM; ≥1.14 in non-DM
Number of subjects: 2089
Study 35965248 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of SHR into the GRACE score
Number of subjects: 2089
Study 35965389 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 507
Study 35965389 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 507
Study 35965389 — intervention group
Group type: COMPARATOR
Intervention: Baseline characteristics
Number of subjects: 507
Study 35965432 — intervention group
Group type: EXPERIMENTAL
Intervention: Darigabat (0.3-10 mg/kg)
Number of subjects: 0
Study 35965432 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (3 and 10 mg/kg)
Number of subjects: 0
Study 35965432 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (PO)
Number of subjects: 0
Study 35965534 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-coverage whole-genome sequencing (LC-WGS) and whole-exome sequencing (WES) of plasma samples.
Number of subjects: 24
Study 35965534 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor genomic analysis (mutation and copy number alteration profiles).
Number of subjects: 24
Study 35965642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 0
Study 35966482 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-oriented trauma treatment for 8 weeks
Number of subjects: 0
Study 35966482 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35966519 — intervention group
Group type: EXPERIMENTAL
Intervention: History of preeclampsia
Number of subjects: 1217
Study 35966519 — intervention group
Group type: COMPARATOR
Intervention: History of normotensive pregnancies
Number of subjects: 1217
Study 35966524 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 98
Study 35966561 — intervention group
Group type: EXPERIMENTAL
Intervention: TAV-in-TAVR with a second supra-annular self-expanding (S-SE) TAVR
Number of subjects: 155
Study 35966561 — intervention group
Group type: EXPERIMENTAL
Intervention: TAV-in-TAVR
Number of subjects: 155
Study 35966841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound phenotype assessment of septic cardiomyopathy
Number of subjects: 0
Study 35966841 — intervention group
Group type: COMPARATOR
Intervention: Normal cardiac ultrasound phenotypes
Number of subjects: 0
Study 35967368 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Number of subjects: 1867
Study 35967368 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2
Number of subjects: 1867
Study 35967368 — intervention group
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Number of subjects: 1867
Study 35967368 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1-S
Number of subjects: 1867
Study 35967368 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronavac
Number of subjects: 1867
Study 35967368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5-nCoV
Number of subjects: 1867
Study 35967368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2
Number of subjects: 1867
Study 35967617 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 60
Study 35967617 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 60
Study 35967820 — intervention group
Group type: EXPERIMENTAL
Intervention: OEA (oleoylethanolamide) daily for 16 months
Number of subjects: 100
Study 35967820 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 16 months
Number of subjects: 100
Study 35967922 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered cognitive-behavioral stress management intervention
Number of subjects: 103
Study 35967922 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (control)
Number of subjects: 103
Study 35968303 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke patients with hypertension
Number of subjects: 869
Study 35968303 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with health care providers prior to stroke onset
Number of subjects: 869
Study 35968303 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication use
Number of subjects: 869
Study 35968314 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish version of the Alberta Infant Motor Scale (AIMS)
Number of subjects: 145
Study 35968440 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial labor analgesia
Number of subjects: 387
Study 35968440 — intervention group
Group type: COMPARATOR
Intervention: No neuraxial labor analgesia (Control)
Number of subjects: 387
Study 35968672 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Block appliance with a check-up every sixth week
Number of subjects: 73
Study 35968672 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Block appliance with a check-up every fourth week
Number of subjects: 73
Study 35968672 — intervention group
Group type: COMPARATOR
Intervention: Twin Block appliance (both groups)
Number of subjects: 73
Study 35968995 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe-injury group (87 biopsies)
Number of subjects: 645
Study 35968995 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-injury group (221 biopsies)
Number of subjects: 645
Study 35968995 — intervention group
Group type: COMPARATOR
Intervention: No-injury group (376 biopsies)
Number of subjects: 645
Study 35968995 — intervention group
Group type: COMPARATOR
Intervention: Mild-injury group (526 biopsies)
Number of subjects: 645
Study 35968995 — intervention group
Group type: COMPARATOR
Intervention: Moderate-injury group (110 biopsies)
Number of subjects: 645
Study 35968995 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell-mediated rejection
Number of subjects: 645
Study 35968995 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antibody-mediated rejection (AMR)
Number of subjects: 645
Study 35968995 — intervention group
Group type: EXPERIMENTAL
Intervention: Late antibody-mediated rejection (AMR)
Number of subjects: 645
Study 35969113 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk oral immunotherapy (OIT)
Number of subjects: 286
Study 35969113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-milk dose group
Number of subjects: 286
Study 35969113 — intervention group
Group type: COMPARATOR
Intervention: Avoidance group
Number of subjects: 286
Study 35969233 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PD-1 plus anti-lymphocyte activation gene 3
Number of subjects: 0
Study 35969233 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous CD8+ tumor-infiltrating lymphocytes (TIL)
Number of subjects: 0
Study 35969233 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+ TILs
Number of subjects: 0
Study 35969416 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35969439 — intervention group
Group type: EXPERIMENTAL
Intervention: Noom Healthy Weight Program
Number of subjects: 600
Study 35969439 — intervention group
Group type: COMPARATOR
Intervention: Noom Healthy Weight Control
Number of subjects: 600
Study 35969451 — intervention group
Group type: EXPERIMENTAL
Intervention: C@nnected group videoconferencing intervention (4 sessions)
Number of subjects: 0
Study 35969451 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual + educational brochures)
Number of subjects: 0
Study 35969451 — intervention group
Group type: EXPERIMENTAL
Intervention: C@nnected group videoconferencing intervention
Number of subjects: 0